Literature DB >> 3499460

Protein kinase C required for cytotoxic T lymphocyte triggering.

T Nishimura1, S J Burakoff, S H Herrmann.   

Abstract

The role of protein kinase C (PK-C) in triggering the lytic response of cytotoxic T lymphocytes (CTL) has been examined. Both target cell lysis and the release of CTL-associated serine esterase (SE), a marker for cytotoxic granules, were used as indicators of the CTL lytic response. We found triggering of the CTL lytic response occurred when both a PK-C activator, phorbol 12-myristate 13-acetate (PMA), and a calcium ionophore, ionomycin, were added to CTL. The previously described inactivation of the CTL lytic response by long term treatment (24 hr) with PMA was also investigated. CTL cultured with PMA for 24 hr were unable to mediate target cell lysis or release SE; this inability to respond correlated with an absence of PK-C activity. Incubation of the PMA-treated CTL in the absence of PMA for an additional 24 hr resulted in recovery of PK-C activity, SE release, and the lytic response. These experiments strongly suggest that PK-C is involved with the transmembrane signaling required for SE release which is a necessary event in CTL-mediated target cell lysis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499460

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Exocytic responses of single leukaemic human cytotoxic T lymphocytes stimulated by agents that bypass the T cell receptor.

Authors:  Arun T Pores-Fernando; Roslyn A Bauer; Georjeana A Wurth; Adam Zweifach
Journal:  J Physiol       Date:  2005-07-14       Impact factor: 5.182

2.  Regulation of IL-4 lymphokine gene expression and cellular proliferation in murine T helper type II cells.

Authors:  E Muñoz; A M Zubiaga; J Muñoz; B T Huber
Journal:  Cell Regul       Date:  1990-04

3.  Rapid loss of perforin and serine protease RNA in cytotoxic lymphocytes exposed to sensitive targets.

Authors:  A Bajpai; B S Kwon; Z Brahmi
Journal:  Immunology       Date:  1991-10       Impact factor: 7.397

4.  Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells.

Authors:  M Nakui; A Ohta; M Sekimoto; M Sato; K Iwakabe; T Yahata; H Kitamura; T Koda; T Kawano; H Makuuchi; M Taniguchi; T Nishimura
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

5.  Increase in Ksp37-positive peripheral blood lymphocytes in mild extrinsic asthma.

Authors:  M Kuepper; K Koester; K Bratke; D Myrtek; K Ogawa; K Nagata; J C Virchow; W Luttmann
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

6.  ERK activation is only one role of PKC in TCR-independent cytotoxic T cell granule exocytosis.

Authors:  Arun T Pores-Fernando; Surabhi Gaur; Michael J Grybko; Adam Zweifach
Journal:  Biochem Biophys Res Commun       Date:  2008-04-14       Impact factor: 3.575

7.  Dietary restriction reduces the incidence of 3-methylcholanthrene-induced tumors in mice: close correlation with its potentiating effect on host T cell functions.

Authors:  A Konno; K Hishinuma; Y Hashimoto; S Kimura; T Nishimura
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers.

Authors:  L M Weiskirch; B A Baumgartel; E Barker; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Protein Kinase C-θ (PKC-θ) in Natural Killer Cell Function and Anti-Tumor Immunity.

Authors:  Alberto Anel; Juan I Aguiló; Elena Catalán; Johan Garaude; Moeez G Rathore; Julián Pardo; Martín Villalba
Journal:  Front Immunol       Date:  2012-07-05       Impact factor: 7.561

10.  Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo.

Authors:  T Nishimura; K Iwakabe; M Sekimoto; Y Ohmi; T Yahata; M Nakui; T Sato; S Habu; H Tashiro; M Sato; A Ohta
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.